February 2018

Important New Products

• Trumenba (meningococcal group B vaccine) prevents meningococcal serogroup B disease ...(more)

New Indications

• Gazyva (obinutuzumab (rch)) in combination with chemotherapy followed by Gazyva ...(more)
• Xalkori (crizotinib) is now indicated for the treatment of ROS1 positive advanced ...(more)

New Contraindications

• Combined oral contraceptives (COCs) including Brevinor, Brevinor-1, Norimin, Norimin-1 ...(more)
• Cervidil (dinoprostone) should not be used or left in place when other labour inducing ...(more)
• Noriday 28 (norethisterone) is now contraindicated with hepatic adenomas or carcinomas. ...(more)
• Prednefrin Forte (prednisolone acetate/phenylephrine hydrochloride) is now ...(more)

Active Ingredient Naming Changes

In this release, MIMS Australia will be including the following INNs (International Non-proprietary Names) as well as Australian Approved Names (AANs) as part of our push to support the Therapeutic Goods Administration (TGA) active ingredient name changes project.  

MIMS will begin referring to these ingredients by their new names, however, users may continue to search by the old AANs if preferred. ...(more)